SKB BIO(06990.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 388.01 million, turned profitable from a loss YoY

NewTimeSpace News: August 17, 2026, SKB BIO(06990.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 978.34 million, increased by 2.93% YoY; Net Profit stood at CNY 388.01 million, turned profitable from a loss YoY; Profit Attributable to Shareholders stood at CNY 388.01 million, turned profitable from a loss YoY; Basic Earnings Per Share (EPS) stood at CNY 1.66.

In terms of profitability, SKB BIO Gross Profit changed from CNY 659.99 million in the same period last year to CNY 736.9 million in the current period, increased by CNY 76.92 million; gross profit margin changed from 69.44% in the same period last year to 75.32% in the current period, increased by 5.88 percentage points; net profit changed from loss of CNY 145.18 million in the same period last year to CNY 388.01 million in the current period, increased by CNY 533.18 million; net profit margin changed from -15.27% in the same period last year to 39.66% in the current period, increased by 54.93 percentage points.

In terms of earnings quality, SKB BIO Operating Profit changed from loss of CNY 172.53 million in the same period last year to CNY 250.03 million in the current period, increased by CNY 422.57 million; Operating Profit Margin changed from -18.15% in the same period last year to 25.56% in the current period, increased by 43.71 percentage points; Net Cash Flow from Operating Activities changed from cash outflow of CNY 373.19 million in the same period last year to cash inflow of CNY 338.8 million in the current period, increased by CNY 711.99 million; Ratio of Net Cash Flow from Operating Activities to Total Operating Revenue changed from -39.27% in the same period last year to 34.63% in the current period, increased by 73.89 percentage points.

In terms of financial soundness, SKB BIO Debt-to-Asset Ratio changed from 15.77% in the same period last year to 15.58% in the current period, decreased by 0.19 percentage points; Total Equity changed from CNY 5.014 billion in the same period last year to CNY 5.337 billion in the current period, increased by CNY 322.56 million; Cash and Cash Equivalents changed from CNY 3.103 billion in the same period last year to CNY 2.776 billion in the current period, decreased by CNY 327.12 million; Current Liabilities changed from CNY 790.35 million in the same period last year to CNY 869.52 million in the current period, increased by CNY 79.17 million; Quick Ratio changed from 6.32 in the same period last year to 6.03 in the current period, decreased by 0.29 percentage points.

In terms of R&D investment focus, SKB BIO R&D Expenses changed from CNY 611.54 million in the same period last year to CNY 768.43 million in the current period, increased by CNY 156.9 million; R&D to Total Revenue Ratio changed from 64.34% in the same period last year to 78.54% in the current period, increased by 14.2 percentage points.

By the close of trading on August 17, 2026, SKB BIO(06990) saw a gain of 0.38% in its share price, closing at HKD 522.5. During the session, it reached an intraday high of HKD 531. The full-day turnover stood at HKD 220.52 million, with the latest market capitalization at HKD 92.39 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.